Published in Infect Immun on February 01, 1995
Exotoxins of Staphylococcus aureus. Clin Microbiol Rev (2000) 7.35
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution. Protein Sci (1996) 0.98
Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect Immun (1995) 0.96
Temporal sequence and kinetics of proinflammatory and anti-inflammatory cytokine secretion induced by toxic shock syndrome toxin 1 in human peripheral blood mononuclear cells. Infect Immun (2001) 0.85
Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells. Infect Immun (1995) 0.81
Staphylococcal superantigen (TSST-1) mutant analysis reveals that t cell activation is required for biological effects in the rabbit including the cytokine storm. Toxins (Basel) (2010) 0.80
A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation. Infect Immun (1995) 0.79
Localization of a T-cell epitope of superantigen toxic shock syndrome toxin 1 to residues 125 to 158. Infect Immun (1998) 0.75
The staphylococcal enterotoxins and their relatives. Science (1990) 11.99
Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis (1981) 8.40
A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet (1981) 7.69
Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A (1979) 6.77
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis (1985) 2.37
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun (1987) 2.13
Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun (1983) 2.08
Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature (1994) 1.67
Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis (1988) 1.63
Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits. Infect Immun (1983) 1.56
Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol (1993) 1.54
Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins. Infect Immun (1991) 1.43
Mediators in the pathogenesis of toxic shock syndrome: overview. Rev Infect Dis (1989) 1.42
Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun (1988) 1.36
Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun (1993) 1.33
The epidemiology of genital colonization with Staphylococcus aureus. Ann Intern Med (1982) 1.32
Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect Immun (1990) 1.31
Selection and characterization of ricin toxin A-chain mutations in Saccharomyces cerevisiae. Mol Cell Biol (1989) 1.30
Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis (1984) 1.28
Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J Infect Dis (1991) 1.06
Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry (1992) 1.05
Distribution and expression of toxic shock syndrome toxin 1 gene among Staphylococcus aureus isolates of toxic shock syndrome and non-toxic shock syndrome origin. Rev Infect Dis (1989) 1.01
Intracellular expression of toxic shock syndrome toxin 1 in Saccharomyces cerevisiae. Infect Immun (1994) 0.80
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis (1983) 1.90
Release of superoxide anion from resident and activated mouse peritoneal macrophages infected with Mycobacterium intracellulare. Am Rev Respir Dis (1984) 1.55
Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine (1998) 1.43
Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol (1996) 1.43
LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol (2000) 1.39
Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J Immunol (1998) 1.38
Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum (1998) 1.37
Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun (1993) 1.33
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum (2000) 1.31
Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol (1993) 1.30
Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages. Proc Natl Acad Sci U S A (2001) 1.24
Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand. Am J Physiol Regul Integr Comp Physiol (2000) 1.17
Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice. J Exp Med (1992) 1.07
Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther (1998) 1.06
Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol (1999) 1.06
Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol (1996) 1.06
Interferon-gamma-induced priming for secretion of superoxide anion and tumor necrosis factor-alpha declines in macrophages from aged rats. FASEB J (1990) 1.03
Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Hum Gene Ther (2000) 0.99
Prevention of age-related T cell apoptosis defect in CD2-fas-transgenic mice. J Exp Med (1995) 0.98
Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. J Med Chem (1996) 0.98
Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha. Infect Immun (1998) 0.97
Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol (1999) 0.97
Role of interferon-gamma in counteracting the suppressive effects of transforming growth factor-beta 2 and glucocorticoids on the production of tumor necrosis factor-alpha. J Leukoc Biol (1990) 0.97
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol (2000) 0.96
Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. Clin Exp Rheumatol (1999) 0.95
Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res (1999) 0.95
Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. Am J Physiol Regul Integr Comp Physiol (2000) 0.93
Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling. Viral Immunol (1999) 0.92
Caspase-3-dependent organ apoptosis early after burn injury. Ann Surg (1999) 0.91
Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus. J Clin Invest (1998) 0.91
Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol (1985) (1998) 0.90
Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol (1999) 0.90
Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol (1997) 0.88
X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J Biol Chem (2000) 0.87
A carbocyclic nucleoside analogue is a TNF-alpha inhibitor with immunosuppressive action: role of prostaglandin E2 and protein kinase C and comparison with pentoxifylline. Cell Immunol (1998) 0.86
Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell Mol Biol (Noisy-le-grand) (1997) 0.86
Phenotype of genetically regulated thymic involution in young BXD RI strains of mice. Scand J Immunol (2006) 0.85
Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int Rev Immunol (1994) 0.85
Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock. J Immunol (1995) 0.83
Visualizing CD4 T-cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model. Br J Dermatol (2009) 0.82
Genetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality. J Endotoxin Res (2001) 0.81
Soluble Fas gene therapy protects against Fas-mediated apoptosis of hepatocytes but not the lethal effects of Fas-induced TNF-alpha production by Kupffer cells. Cell Death Differ (2002) 0.81
Defective Fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection. Arthritis Rheum (2001) 0.81
Glucocorticoid and Fas ligand induced mucosal lymphocyte apoptosis after burn injury. J Trauma (2000) 0.81
In vivo effects of recombinant interferon-gamma: augmentation of endotoxin-induced necrosis of tumors and priming of macrophages for tumor necrosis factor-alpha production. Cancer Lett (1990) 0.79
Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. Behring Inst Mitt (1996) 0.79
Specific transcriptional inhibition of bone marrow-derived macrophage tumor necrosis factor-alpha gene expression and protein production using novel enantiomeric carbocyclic nucleoside analogues. J Pharmacol Exp Ther (1995) 0.78
Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J Infect Dis (2000) 0.78
Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. J Appl Physiol (1985) (2001) 0.78
Murine models of autoimmune disease. Curr Opin Rheumatol (1992) 0.77
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis (2000) 0.77
Murine models of autoimmunity: T-cell and B-cell defects. Curr Opin Rheumatol (1992) 0.77
A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice. Pathobiology (1995) 0.76
T cell influence on superantigen-induced arthritis in MRL-lpr/lpr mice. Arthritis Rheum (1994) 0.75
Autoimmunity due to defective Nur77, Fas, and TNF-RI apoptosis. Adv Exp Med Biol (1996) 0.75
TNF-alpha blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses. Immunopharmacol Immunotoxicol (2000) 0.75
The respiratory burst in activated macrophages: studies of its molecular basis and evidence for downregulation in chronic infection. Adv Exp Med Biol (1988) 0.75
Discriminant function analysis of body surface potential maps in acute myocardial infarction. J Electrocardiol (1994) 0.75
Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte beta-adrenergic receptors. Biochem Pharmacol (1987) 0.75